On Jun. 18, 2008, Fred Hutch researchers described the first successful use of a human patient’s cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission.

A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reported these findings in the New England Journal of Medicine.